<em>ROS1</em> in the Driver’s Seat: Emerging Science and Evolving Strategies in the Treatment of <em>ROS1</em>-Positive NSCLC
E-Publication E-Publication

ROS1 in the Driver’s Seat: Emerging Science and Evolving Strategies in the Treatment of ROS1-Positive NSCLC


Released:
4/24/19
Expires:
4/23/20

Maximum Credits:

0.5
By clicking "Continue," you are confirming that you have reviewed the CME information and read, understood, and unconditionally agreed to the Privacy Notice and Terms of Use.

E-Publication E-Publication
By clicking "Continue," you are confirming that you have reviewed the CME information and read, understood, and unconditionally agreed to the Privacy Notice and Terms of Use.
Released:
4/24/19

Expires:
4/23/20

Maximum Credits:
0.5
E-Publication E-Publication
By clicking "Continue," you are confirming that you have reviewed the CME information and read, understood, and unconditionally agreed to the Privacy Notice and Terms of Use.

Released:
4/24/19
Expires:
4/23/20


Maximum Credits:
0.5


Overview: This publication reviews ROS1 gene fusions as an oncogenic driver of non–small cell lung cancer (NSCLC) and available methods for detecting these rearrangements in patients with advanced NSCLC. Data surrounding emerging tyrosine kinase inhibitors (TKIs) that are effective against ROS1-positive NSCLC are also explored. Additionally, audio clips of faculty are incorporated to provide expert perspectives. This publication also includes short whiteboard-style video animations that describe ROS1 rearrangements and mechanisms of resistance to crizotinib therapy.

CME Information:

Faculty
Alice T. Shaw, MD, PhD
Director, Center for Thoracic Cancers
Massachusetts General Hospital
Professor of Medicine
Harvard Medical School
Boston, MA

Activity Planners
Christie Avraamides, PhD
Clinical Content Manager
Med-IQ
Baltimore, MD

Laura Rafferty, ELS
Managing Editor
Med-IQ
Baltimore, MD

Samantha Gordon
CME Specialist
Med-IQ
Baltimore, MD

Kathryn Schaefer, MSN, RN, CPHRM
Senior Manager, Accreditation and Compliance
Med-IQ
East Lansing, MI

Writer
Stephanie Wenick, MPhil
Wenick Communications, LLC
Chevy Chase, MD

Learning Objective
Upon completion, participants should be able to:

  • Describe various molecular tests to detect ROS1 rearrangements
  • Apply available and emerging data on ROS1 TKIs to treatment decisions for patients with ROS1-positive NSCLC

Target Audience
This activity is intended for oncologists.
 
Statement of Need
Approximately 1% to 2% of patients with NSCLC harbor ROS1 rearrangements. Oncologists face several challenges related to the optimal selection of appropriate ROS1 molecular testing and application of the results in clinical practice, which may prevent some patients from receiving treatment specific to their disease’s molecular signature. Therefore, oncologists need education on appropriately testing and identifying patients who could benefit from ROS1 targeted therapy. Crizotinib is currently the only therapy approved by the United States Food and Drug Administration for the treatment of patients whose tumors contain ROS1 rearrangements. Unfortunately, a high percentage of patients with ROS1-positive NSCLC will develop resistance to crizotinib therapy and experience disease progression. Subsequent targeted therapeutic options are currently limited; however, multiple therapies are being investigated for the treatment of ROS1-rearranged NSCLC in both the TKI-naïve and post-crizotinib settings. Oncologists must be familiar with available and emerging clinical data on ROS1 TKIs in order to be prepared to make decisions about drug selection and sequencing for patients with ROS1-positive NSCLC as new targeted therapies emerge.
 
Providership Statement
Provided by Med-IQ.

Accreditation/Designation Statement
Med-IQ is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Med-IQ designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse practitioners, physician assistants, and other healthcare professionals who successfully complete the activity will receive a Statement of Participation indicating the maximum credits available.
 
Medium/Method of Participation
This CME activity consists of a 0.5-credit online publication. To receive credit, read the introductory CME material, read the publication, and complete the post-survey, evaluation, attestation, and post-test, answering at least 70% of the post-test questions correctly.
 
Initial Release Date: April 24, 2019
Expiration Date: April 23, 2020
Estimated Time to Complete This Activity: 30 minutes
 
Disclosure Policy
Med-IQ requires any person in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as those in any amount occurring within the past 12 months, including those of a spouse/life partner, that could create a conflict of interest (COI). Individuals who refuse to disclose will not be permitted to contribute to this CME activity in any way. Med-IQ has policies in place that will identify and resolve COIs prior to this educational activity. Med-IQ also requires faculty to disclose discussions of investigational products or unlabeled/unapproved uses of drugs or devices regulated by the US Food and Drug Administration.
 
Disclosure Statement
The content of this activity has been peer reviewed and has been approved for compliance. The faculty and contributors have indicated the following financial relationships, which have been resolved through an established COI resolution process, and have stated that these reported relationships will not have any impact on their ability to give an unbiased presentation.
 
Alice T. Shaw, MD, PhD
Consulting fees/advisory boards: Bayer HealthCare Pharmaceuticals, Blueprint Medicines Corporation, Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo, Co., Ltd., EMD Serono, Inc., F. Hoffmann-La Roche Ltd., Genentech, Ignyta, Inc., KSQ Therapeutics, Loxo Oncology, Natera, Inc., Novartis Pharmaceuticals Corporation, Pfizer, Inc., Taiho Pharmaceutical Co, Ltd., Takeda Pharmaceuticals North America, Inc., Turning Point Therapeutics, Inc.
Contracted research: F. Hoffmann-La Roche Ltd., Genentech, Ignyta, Inc., Novartis Pharmaceuticals Corporation, Pfizer, Inc., Takeda Pharmaceuticals North America, Inc., Turning Point Therapeutics, Inc.

The writer, peer reviewers, and activity planners have no financial relationships to disclose.

Statement of Evidence-Based Content
Educational activities that assist physicians in carrying out their professional responsibilities more effectively and efficiently are consistent with the ACCME definition of continuing medical education (CME). As an ACCME-accredited provider of CME, Med-IQ has a policy to review and ensure that all the content and any recommendations, treatments, and manners of practicing medicine in CME activities are scientifically based, valid, and relevant to the practice of medicine. Med-IQ is responsible for validating the content of the CME activities it provides. Specifically, (1) all recommendations addressing the medical care of patients must be based on evidence that is scientifically sound and recognized as such within the profession; (2) all scientific research referred to, reported, or used in CME in support or justification of a patient care recommendation must conform to generally accepted standards of experimental design, data collection, and analysis.
 
Med-IQ is not liable for any decision made or action taken in reliance upon the information provided through this activity.

Contact Information        
For questions or comments about this activity, please contact Med-IQ. Call (toll-free) 866 858 7434 or email info@med-iq.com.

System Requirements
Desktop

Mobile

  • Operating system - Med-IQ supports the current operating system, plus two prior releases:
    • Android (eg, Samsung Galaxy)
    • Apple (eg, iPhone/iPad)
  • Browsers - Med-IQ supports the default browser for the applicable operating system release, plus two prior releases:
    • Android (Chrome)
    • Apple (Safari)

Applications & Software

For technical assistance, please refer to our Support Manual.

ADA Statement
Med-IQ fully complies with the legal requirements of the ADA and the rules and regulations thereof. If any participant in this educational activity is in need of accommodations, please contact Med-IQ at 443 543 5200.
 
Disclaimer
The information provided through this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Privacy & Confidentiality
Med-IQ is committed to honoring your privacy and protecting any personal information you choose to share with us. For detailed information about our privacy policy, please visit: www.med-iq.com/privacy-policy.html.

Acknowledgment of Commercial Support
This activity is supported by an educational grant from Genentech.

Copyright
© 2019 Med-IQ, Inc.

Unless otherwise indicated, photographed subjects who appear within the content of this activity or on artwork associated with this activity are models; they are not actual patients or doctors.

Need help? If you need to speak with a member of our team, please call (toll-free) 866 858 7434 or email info@med-iq.com. For technical assistance, please refer to our support manual.